drugset / Trial / NCT04295161

A Study Designed to Evaluate the Pharmacokinetic Profile of Abiraterone

NCT04295161

Phase 1 Completed 33 enrolled Zentiva, k.s.
RandomizedCrossoverOpen-labelTreatment

Summary

A Study in Healthy Male Subjects Designed to Evaluate the Pharmacokinetic Profile of Abiraterone Following Administration of Immediate Release Formulations

Timeline

Start
2019-06-25
Primary completion
2019-11-08
Completion
2019-11-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Abiraterone acetate Small molecule

Indications

No indication recorded.